Alecensa (Alectinib)

Brand Name

Alecensa

Generic Name

Alectinib

View Brand Information

FDA approval date: December 11, 2015

Classification: Kinase Inhibitor

Form: Capsule

What is Alecensa (Alectinib)?

ALECENSA is a kinase inhibitor indicated for: adjuvant treatment in adult patients following tumor resection of anaplastic lymphoma kinase -positive non-small cell lung cancer as detected by an FDA-approved test.

Approved To Treat

Top Global Experts

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Related Clinical Trials

NAUTIKA1: A Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-selected Patients With Resectable Stages IB-III Non-small Cell Lung Cancer

Who is this study for: Patients with operable Stage IIA, IIB, IIIA, and select IIIB resectable and untreated non-small cell lung cancer tumors with selected molecular alterations

Enrollment Status: Recruiting

Publish Date: June 09, 2026

Intervention Type: Drug, Procedure

Study Drugs: Alectinib, Entrectinib, Vemurafenib, Cobimetinib, Chemotherapy, Pralsetinib

Study Phase: Phase 2

Summary: This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.

A Phase 1b Study of Gilteritinib in Participants With Locally Advanced or Metastatic NSCLC With ALK Rearrangement After Prior Treatment With an ALK Inhibitor

Enrollment Status: Recruiting

Publish Date: June 08, 2026

Intervention Type: Drug

Study Phase: Phase 1

Summary: Genes give your body instructions on how to make proteins. Proteins are needed to keep the body working properly. Many types of cancer are caused by changes in certain genes, making them faulty. Some people with non small cell lung cancer (NSCLC) have a faulty ALK gene. ALK stands for anaplastic lymphoma kinase. People with NSCLC who have the faulty ALK gene are called ALK-positive. ALK inhibitors...

Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy in China: A Multicenter, Prospective Cohort Study

Enrollment Status: Recruiting

Publish Date: June 04, 2026

Intervention Type: Drug

Summary: This study is a multicenter, prospective, cohort study designed to evaluate the clinical outcomes and characteristics of resected stage II-IIIB anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) adult patients treated with Alectinib as adjuvant therapy in China.

View All Clinical Trials

Related Latest Advances

Optimal Use of Targeted Therapy and Immunotherapy in Early-Stage, Resectable Non-Small Cell Lung Cancer.

Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Published: June 23, 2026

Inflammatory Myofibroblastic Tumor: A Case Report of Neoadjuvant Alectinib and Summary of Single-Institution Molecular Data.

Journal: JCO precision oncology

Published: June 08, 2026

Perioperative Molecular Testing in Non-small Cell Lung Cancer

Journal: Zentralblatt fur Chirurgie

Published: June 08, 2026

View All Latest Advances

Brand Information

ALECENSA (ALECTINIB HYDROCHLORIDE)

1DOSAGE FORMS AND STRENGTHS

150 mg hard capsules, white, with "ALE" printed in black ink on the cap and "150 mg" printed in black ink on the body.

2CONTRAINDICATIONS

None.

3ADVERSE REACTIONS

The following adverse reactions are discussed in greater detail in other sections of the label:

Hepatotoxicity
Interstitial Lung Disease (ILD)/Pneumonitis
Renal Impairment
Bradycardia
Severe Myalgia and Creatine Phosphokinase (CPK) Elevation
Hemolytic Anemia
Embryo-Fetal Toxicity

3.1Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The pooled safety population described in the WARNINGS AND PRECAUTIONS reflects exposure to ALECENSA as a single agent at 600 mg orally twice daily in 533 patients in Studies NP28761, NP28673, ALEX and ALINA

4OVERDOSAGE

No experience with overdose is available. There is no specific antidote for overdose with ALECENSA. Alectinib and its major active metabolite M4 are > 99% bound to plasma proteins; therefore, hemodialysis is likely to be ineffective in the treatment of overdose.

5DESCRIPTION

ALECENSA (alectinib) is a kinase inhibitor for oral administration. The molecular formula for alectinib is C

Alectinib HCl is a white to yellow white powder or powder with lumps with a pKa of 7.05 (base).

ALECENSA is supplied as hard capsules containing 150 mg of alectinib (equivalent to 161.33 mg alectinib HCl) and the following inactive ingredients: lactose monohydrate, hydroxypropylcellulose, sodium lauryl sulfate, magnesium stearate, and carboxymethylcellulose calcium. The capsule shell contains hypromellose, carrageenan, potassium chloride, titanium dioxide, corn starch, and carnauba wax. The printing ink contains red iron oxide (E172), yellow iron oxide (E172), FD&C Blue No. 2 aluminum lake (E132), carnauba wax, white shellac, and glyceryl monooleate.

6HOW SUPPLIED/STORAGE AND HANDLING

Hard capsules, white 150 mg capsules with "ALE" printed in black ink on the cap and "150 mg" printed in black ink on the body, available in:

7PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Inform patients of the following:

8PRINCIPAL DISPLAY PANEL - 150 mg Capsule Bottle Carton

NDC 50242-130-01

Alecensa

150 mg

Each capsule contains 150 mg of alectinib

Rx only

240 capsules

Genentech

11008914

PRINCIPAL DISPLAY PANEL - 150 mg Capsule Bottle Carton